Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Prostate Cancer DREAM Challenge

Using the proven DREAM methodology, Project Data Sphere, LLC (PDS) and Sage Bionetworks conducted the Prostate Cancer DREAM Challenge (PCDC) in 2015. The PCDC used curated data from four phase III trials studying metastatic Castrate Resistant Prostate Cancer (mCRPC) from the Project Data Sphere platform.

Prostate Cancer DREAM Challenge

Participants were asked to predict overall survival for mCRPC using patients clinical variables at baseline, and to predict treatment discontinuation for mCRPC patients treated with docetaxel due to adverse events. More DREAM solvers participated in the PCDC than any other DREAM Challenge to date, and the best performing teams produced exciting improvements on existing prognostic models.

PDS is excited to make the PCDC data available to the entire research community for further research during the Public Leaderboard period. After registering for access, users can access the PCDC data, develop their own prognostic models, and submit those models on the PCDC Synapse page for scoring.